bioAffinity Technologies (BIAF) Stock Price, News & Analysis

Company Overview

bioAffinity Technologies, Inc. (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications. By enriching and detecting rare circulating tumor cells and cell-free DNA fragments, bioAffinity’s diagnostic tests seek to identify malignancies at stages when treatment options may be more effective. In addition to breast cancer diagnostics, bioAffinity is actively researching assays for ovarian cancer and exploring applications in other tumor types, as well as monitoring minimal residual disease following therapy.

Headquartered in Houston, Texas, bioAffinity maintains research and development facilities in the United States and collaborates with leading academic medical centers to validate its diagnostic assays. Since its inception, the company has secured multiple patents covering its nanoparticle-based enrichment methods and bioaffinity reagents. Under the leadership of CEO Dr. Chee Lee, bioAffinity has pursued strategic partnerships and clinical studies to support regulatory filings and commercial launch activities.

Looking ahead, bioAffinity Technologies is focused on expanding its footprint in the U.S. market while exploring international licensing and distribution agreements. Through continued investment in R&D and collaborative clinical validation, the company aims to advance its next-generation diagnostic offerings, address unmet needs in cancer care, and contribute to the broader adoption of precision oncology solutions.

Key Stats

• Today's Range: $1.87 to $2.00
• 50-Day Range: $1.03 to $4.74
• 52-Week Range: $0.69 to $15.00
• Volume: 155,279 shs
• Average Volume: 394,111 shs
• Market Capitalization: $9.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

bioAffinity Technologies Stock Analysis - MarketRank™

bioAffinity Technologies scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

bioAffinity Technologies has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

bioAffinity Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of bioAffinity Technologies is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of bioAffinity Technologies is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

bioAffinity Technologies has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.45% of the float of bioAffinity Technologies has been sold short.

Short Interest Ratio / Days to Cover

bioAffinity Technologies has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in bioAffinity Technologies has recently increased by 31.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bioAffinity Technologies does not currently pay a dividend.

Dividend Growth

bioAffinity Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.81

News Sentiment

bioAffinity Technologies has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for bioAffinity Technologies this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 3 people have added bioAffinity Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bioAffinity Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.68% of the stock of bioAffinity Technologies is held by insiders.

Percentage Held by Institutions

1.64% of the stock of bioAffinity Technologies is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/15/2026
• Next Earnings (Estimated): 5/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:BIAF
• CIK: 1712762
• Web: www.bioaffinitytech.com
• Phone: 210-698-5334
• Fax: N/A
• Employees: 10
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($11.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.91 million
• Net Margins: -280.53%
• Pretax Margin: -279.90%
• Return on Equity: -285.75%
• Return on Assets: -143.71%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.36
• Quick Ratio: 2.58

Sales & Book Value

• Annual Sales: $6.16 million
• Price / Sales: 1.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 2.46

Miscellaneous

• Outstanding Shares: 4,530,000
• Free Float: 4,413,000
• Market Cap: $9.01 million
• Optionable: Not Optionable
• Beta: -1.19